LB Pharmaceuticals
LBRX
34.16
-0.10
-0.29%
LB Pharmaceuticals
US · LBRX
#3180 by market cap
Listed 2025
34.16
-0.10
-0.29%
Live - 5344 symbols - heartbeat 285s ago
· 2026-10-08 09:09
Pre-market
33.48
-1.99%
After-hours
34.16
0.00%
- Market cap
- 1.10B
- P/E (TTM)i
- -11.43
- P/Bi
- 3.32
- EPSi
- -1.00
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on LBRX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 4 years
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 1.46M | 3.53M | 13.66M | 13.66M |
| Research & development | 1.35M | 7.85M | 51.17M | 16.74M |
| Operating profit | -2.81M | -11.38M | -64.83M | -30.40M |
| Pretax profit | -14.35M | -6.27M | -63.10M | -25.20M |
| Tax | 1.00K | 1.00K | 1.00K | 1.00K |
| Net profit | -14.35M | -6.28M | -63.10M | -25.21M |
| Basic EPS | -4 | -2 | -18 | -3 |
| Diluted EPS | -4.05 | -1.77 | -17.82 | -3.13 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.01M | 2.44M | 2.83M | 5.39M | 7.46M | 9.77M |
| Research & development | 3.42M | 2.42M | 2.42M | 8.48M | 14.65M | 44.15M |
| Operating profit | -6.43M | -4.86M | -5.25M | -13.87M | -22.10M | -53.92M |
| Pretax profit | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M |
| Tax | 0 | 0 | 0 | 1.00K | 0 | 0 |
| Net profit | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M |
| Basic EPS | 0 | 0 | -1 | 0 | -1 | -2 |
| Diluted EPS | -0.24 | -0.22 | -0.61 | -0.45 | -0.67 | -1.71 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 21.49M | 45.63M | 28.88M | 308.43M |
| Cash & ST investments | 21.40M | 43.29M | 28.00M | 295.21M |
| Inventory | -- | -- | -- | -- |
| Total assets | 21.49M | 45.66M | 33.53M | 312.93M |
| Total current liabilities | 469.00K | 2.61M | 8.11M | 7.44M |
| Short-term debt | -- | -- | 487.00K | 730.00K |
| Long-term debt | 24.15M | -- | -- | -- |
| Total liabilities | 50,304,000.00 | 80,130,000.00 | 128,088,000.00 | 11,624,000.00 |
| Total equity | -28.81M | -34.47M | -94.55M | 301.31M |
| Retained earnings | -34.95M | -41.22M | -104.32M | -129.53M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 14.78M | 316.40M | 308.43M | 389.07M | 355.30M |
| Cash & ST investments | -- | 14.23M | 314.48M | 295.21M | 365.64M | 327.79M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | 19.25M | 320.75M | 312.93M | 393.48M | 361.69M |
| Total current liabilities | -- | 3.91M | 6.65M | 7.44M | 10.91M | 23.56M |
| Short-term debt | -- | 730.00K | 730.00K | 730.00K | 730.00K | 844.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | 123,121,000.00 | 10,525,000.00 | 11,624,000.00 | 14,789,000.00 | 29,345,000.00 |
| Total equity | -- | -103.87M | 310.22M | 301.31M | 378.69M | 332.35M |
| Retained earnings | -- | -114.50M | -118.06M | -129.53M | -148.58M | -200.19M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -2.73M | -12.09M | -53.05M | -35.21M |
| Depreciation & amortization | 2.00K | 4.00K | 91.00K | 321.00K |
| Free cash flow | -2.73M | -12.12M | -53.82M | -35.26M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 327.75M |
| Ending cash balance | 21.40M | 14.98M | 23.48M | 250.94M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -8.13M | -5.60M | -3.37M | -18.10M | -23.29M | -37.63M |
| Depreciation & amortization | 79.00K | 76.00K | 81.00K | 85.00K | 82.00K | 97.00K |
| Free cash flow | -8.15M | -5.60M | -3.37M | -18.14M | -23.32M | -37.99M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 327.75M | 0 | 100.00M | 0 |
| Ending cash balance | 20.33M | 14.73M | 270.26M | 250.94M | 321.45M | 283.89M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -24.38 |
| ROA %i | -66.76 | -18.69 | -159.37 | -14.55 |
| ROIC %i | -- | -- | -- | -27.22 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 45.82 | 17.51 | 3.56 | 41.44 |
| Quick ratioi | 45.64 | 16.61 | 3.45 | 39.67 |
| Debt / assetsi | 112.36 | 0.00 | 11.04 | 1.14 |
| LT debt / equityi | -- | -- | -- | 0.94 |
| Interest coveragei | -5.67 | -0.30 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -6.06 | -24.38 | -10.29 | -75.01 |
| ROA %i | -- | -152.89 | -5.86 | -14.55 | -9.90 | -44.99 |
| ROIC %i | -- | -- | -6.33 | -27.22 | -11.22 | -76.89 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | 3.78 | 47.60 | 41.44 | 35.68 | 15.08 |
| Quick ratioi | -- | 3.64 | 47.31 | 39.67 | 33.53 | 13.91 |
| Debt / assetsi | -- | 19.54 | 1.14 | 1.14 | 0.88 | 1.44 |
| LT debt / equityi | -- | -- | 0.95 | 0.94 | 0.72 | 1.32 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 09:09:08 · For reference only, not investment advice and not tailored to your situation.